Ensign Peak Advisors
GNMK

Ensign Peak Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

Ensign Peak Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,669
Closed -$279K – 1897
2020
Q3 		$279K Buy
+19,669
New +$301K ﹤0.01% 1634

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ensign Peak Advisors's GNMK Position: Q4 2020 in Review

Ensign Peak Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 19,669 shares — an estimated $279K sold.

Ensign Peak Advisors first reported a position in GNMK in Q3 2020 and held it in 1 quarter. The position peaked at $279K in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Ensign Peak Advisors reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • Ensign Peak Advisors sold 19,669 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $279K.
  • Ensign Peak Advisors first reported a position in GenMark Diagnostics, Inc in Q3 2020 and held it in 1 quarter.
  • Ensign Peak Advisors's GenMark Diagnostics, Inc position peaked at $279K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Ensign Peak Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.